Arriva Pharmaceuticals Inc., an Alameda, Calif.-based developer of anti-inflammatory therapies for treating respiratory disease, has raised $6 million in new funding from Nordic Biotech and return backer MPM Capital. The company has now raised $81 million in total funding. www.arrivapharma.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.